Pre-Clinical Production and Initial Process Development for CBI-3A Vaccine Adjuvant
NCBiotech Grants & Loans
See the full listing of all NCBiotech grants and loans awarded since July 2012.
Organization
Clarus Biologics, Inc.
Award Date
Award Amount
250,000
Program Name
Small Business Research Loan
Program Category
Business Financing
Principal Investigator
Peter Anderson
Fiscal Year
2022
Region
Research Triangle
Project Description:
Clarus Biologics is developing a genetically modified RNA alphavirus as a vaccine adjuvant to enhance the magnitude, breadth and durability of the immune response. The company has been awarded a $250,000 loan to execute process development activities and produce GLP-quality adjuvant for characterization assays and stability testing.